Table 4.
Comparison of lipid profiles in postmenopausal BC patients.
| TC β (95%CI) | TG β (95%CI) | LDL change β (95%CI) | HDL β (95%CI) | |
|---|---|---|---|---|
| ET | ||||
| control | 0.00 | 0.00 | 0.00 | 0.00 |
| TAM | -0.14 (-0.43,0.14) | -0.01 (-0.31,0.30) | -0.50 (-0.77,-0.24) | 0.14 (-0.39,0.67) |
| LET | -0.05 (-0.28,0.19) | -0.14 (-0.39,0.12) | -0.02 (-0.25,0.22) | 0.01 (-0.48,0.51) |
| ANA | 0.02 (-0.23,0.28) | -0.12 (-0.40,0.15) | 0.03 (-0.22,0.28) | 0.06 (-0.47,0.59) |
| EXE | -0.05 (-0.35,0.25) | -0.26 (-0.57,0.06) | -0.19 (-0.49,0.12) | 0.06 (-0.54,0.66) |
| Time | -0.01 (-0.04,0.03) | -0.06 (-0.10,-0.03) | -0.02 (-0.05,0.01) | 0.05 (-0.07,0.17) |
| ET*Time | ||||
| control*time | 0.00 | 0.00 | 0.00 | 0.00 |
| TAM*time | -0.03 (-0.08,0.01) | 0.05 (-0.001,0.10) | 0.06 (0.02,0.11) | -0.07 (-0.24,0.09) |
| LET*time | 0.01 (-0.04,0.06) | 0.06 (0.00,0.11) | -0.01 (-0.06,0.04) | -0.03 (-0.21,0.15) |
| ANA*time | 0.00 (-0.05,0.06) | 0.01 (-0.05,0.06) | -0.01 (-0.06,0.04) | -0.02 (-0.21,0.16) |
| EXE*time | 0.00 (-0.06,0.06) | 0.04 (-0.03,0.10) | 0.05 (-0.005,0.11) | -0.07 (-0.27,0.14) |
| Chemotherapy | ||||
| anthracycline-plus-taxane-based regimens | 0.00 | 0.00 | 0.00 | 0.00 |
| anthracycline-based regimens | -0.20 (-0.53,0.13) | -0.10 (-0.45,0.25) | 0.31 (0.02,0.61) | -0.05 (-0.57,0.46) |
| taxane-based regimens | 0.16 (-0.27,0.59) | -0.07 (-0.52,0.38) | -0.32 (-0.70,0.05) | -0.13 (-0.77,0.50) |
| Smoking | ||||
| No | 0.00 | 0.00 | 0.00 | 0.00 |
| Yes | 0.28 (0.00,0.55) | 0.10 (-0.19,0.39) | -0.12 (-0.36,0.13) | -0.01 (-0.42,0.41) |
| Hypertension | ||||
| No | 0.00 | 0.00 | 0.00 | 0.00 |
| Yes | -0.03 (-0.25,0.19) | -0.05 (-0.29,0.18) | 0.12 (-0.07,0.32) | -0.08 (-0.42,0.25) |
| Age | 0.01 (0.00,0.02) | 0.00 (-0.01,0.01) | -0.001 (-0.01,0.01) | 0.00 (-0.02,0.01) |
| BMI | -0.00 (-0.03,0.02) | 0.05 (0.02,0.07) | 0.01 (-0.01,0.03) | -0.03 (-0.06,0.01) |